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lies attributable to disordered steroidogenesis, no mor-
phologic feature distinguished patients with POR mu-
tations from those with FGFR mutations” (Huang et al.
2005, p. 736)—may not be warranted.
Continuing to use the term “ABS” for patients with
FGFR mutations will only contribute to the confusion
that is already present in the literature. The concern is
that this confusion may interfere with proper patient man-
agement and counseling, both of which depend on the
ability of clinicians and researchers to clearly recognize,
understand, and convey to patients the differences be-
tween POR deficiency and FGFR-related craniosynosto-
sis syndromes.
Use of the term “ABS” to describe patients with POR
deficiency who are at the more severe end of the pheno-
typic spectrum can be clinically useful in distinguishing
them from patients with POR deficiency who have mild
or no skeletal defects (Arlt et al. 2004; Flu¨ck et al. 2004;
Fukami et al. 2004). We believe it would be better to
reserve the use of the term “ABS” for patients with POR
deficiency and clinically significant craniosynostosis and/
or radiohumoral synostosis.
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“Antley-Bixler Syndrome”—A Reply to Cragun
and Hopkin
To the Editor:
Cragun and Hopkin (2005 [in this issue]) raise a series
of points concerning use of the term “Antley-Bixler syn-
drome” (ABS), both in our recent paper in this journal
(Huang et al. 2005) and elsewhere. We agree that it is
useful to minimize confusion: the best way to do this may
be to discard the term “ABS” and other eponymic terms
once the molecular genetics and cell biology of a disease
have been worked out. However, until such eponyms are
discarded, as stated in our paper, “we propose that the
term ‘ABS’ be reserved for those patients with the skeletal
dysmorphologic findings initially reported by Antley and
Bixler (1975) but who have normal genitalia and normal
steroidogenesis” (Huang et al. 2005, p. 745). Cragun
and Hopkin suggest that “patients with FGFR mutations
should be grouped with those with other autosomal domi-
nant FGFR-related craniosynostosis syndromes.” We
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Table 1
Genotype/Phenotype Correlations Collated from the Data in Tables
1 and 4 of Huang et al. (2005)
GENOTYPE









Craniosynostosis 4/4 14/15 8/8 3/3
Brachycephaly … 7/10 5/5 1/2
RU/RHa synostosis 4/4 13/15 6/7 2/3
Femoral bowing 3/3 9/13 3/6 2/2
Femoral fractures 0/1 2/10 2/3 1/2
Midface hypoplasia 2/2 9/10 8/8 2/2
Proptosis 1/1 9/11 8/9 3/3
Rocker-bottom feet … 4/9 0/1 1/1
Arachnodactyly 2/2 7/11 0/3 1/1
Camptodactyly … 3/6 2/5 …
Choanal atresia 1/1 7/9 7/8 3/3
Abnormal steroids 2/2 8/8 … …
Abnormal genitalia 2/2 10/10 … …
NOTE—The column designations (from table 4 of Huang et al.
[2005]) indicate whether a mutation was found on only one of the
two POR alleles (1 POR), both alleles (2 POR), on one allele of
FGFR2, or whether no mutation was found on either gene. The clinical
findings are from table 1 (Huang et al. 2005); since each finding was
not commented on in all the case histories, the denominators vary. Of
the findings described in the available clinical data, only the presence
of an abnormality in steroidogenesis or in genital development distin-
guished the patients with POR mutations from those with FGFR2
mutations.
a RH p radiohumeral; RU p radioulnar.
agree. Describing dysmorphologic disorders by eponyms
was appropriate when the responsible genes were not
known, but little purpose is served in preserving these
terms once the molecular genetics and cell biology are
delineated. Although one may wish to honor investiga-
tors with eponyms, such nosology inhibits understand-
ing of mechanisms: “post-streptococcal glomerulonephri-
tis” may be less euphonious than “Bright’s disease” but
is more specific and informative.
Cragun and Hopkin raise questions about the patient
initially described by Antley and Bixler and about several
other reported cases. Clearly, it is difficult (if not impossi-
ble) to make or exclude a diagnosis retrospectively. Lack-
ing the individual’s DNA, we cannot know the molecular
lesion in the patient described by Antley and Bixler (but
we’d be happy to study it!). Whereas Cragun and Hop-
kin lament the paucity of published photographs and
clinical detail in many case reports, we lament the poor
descriptions of the external genitalia and the incomplete
hormonal evaluations in most patients with “ABS.” Care-
ful steroidal evaluation is crucial: mass spectrometric an-
alysis of urinary steroids is highly reliable but not widely
available; appropriate evaluation of pre- and poststimu-
lation plasma steroids is equally reliable. The data avail-
able to Reardon et al. (2000) were insufficient to estab-
lish or exclude a steroidogenic disorder for several of
their patients; hence, their report does not provide evi-
dence for the suggestion that POR (P450 oxidoreduc-
tase) mutations might cause a skeletal disorder associated
with normal genitalia. Thus, we believe that our con-
clusion that “aside from the genital anomalies attribut-
able to disordered steroidogenesis, no dysmorphological
feature distinguished patients with POR mutations from
those with FGFR mutations” (Huang et al. 2005, p. 736)
is well supported by the data in table 1 of Huang et al.
(2005, p. 731). For convenience, we have compiled the
clinical data from table 1 and the genetic data from table
4 (p. 737) in the table shown here. More-refined obser-
vations may identify other anatomic features distinguish-
ing POR from FGFR mutations in infants with cranio-
synostosis; however, our data clearly show that dysmor-
phologists must pay very close attention to the external
genitalia in these children and consider evaluation of ste-
roid secretion before and after tropic stimulation with
adrenocorticotropic hormone.
Deficient POR activity can cause a broad spectrum of
human disease (Flu¨ck et al. 2004; Miller 2004; Huang
et al. 2005), and clearly the patients described by us and
others who have POR lesions without skeletal defects
do not have ABS. Thus, we do not think it is reasonable
to follow the suggestion of Cragun and Hopkin to use
the term “ABS” for patients with the more severe form
of POR deficiency associated with skeletal anomalies. If,
as they propose (and we agree), all FGFR-based cranio-
synostosis disorders should be grouped together, then it
is logical to group all POR disorders together. Regardless
of whether the clinical genetics community agrees to dis-
card eponyms in favor of a term such as “FGFR hyper-
activity,” we believe that “POR deficiency,” which is a
newly described monogenic disease, should be dissoci-
ated from the term “Antley-Bixler Syndrome.”
WALTER L. MILLER
Department of Pediatrics,
University of California, San Francisco (UCSF),
and UCSF Children’s Hospital, San Francisco
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LRRK2 Haplotype Analyses in European and North
African Families with Parkinson Disease: A Common
Founder for the G2019S Mutation Dating
from the 13th Century
To the Editor:
Parkinson disease [PD (MIM 168600)] is the second most
common neurodegenerative disorder, characterized by
resting tremor, rigidity, bradykinesia, and gait distur-
bances. The LRRK2 gene (GenBank accession number
AY792511) was recently identified as being responsible
for autosomal dominant PD (Paisan-Ruiz et al. 2004;
Zimprich et al. 2004). Several groups have reported that
a single pathogenic G6055A substitution (G2019S) in
the LRRK2 gene was associated with 3%–6% and 1%–
2% of familial and sporadic PD, respectively (Di Fonzo
et al. 2005; Gilks et al. 2005; Kachergus et al. 2005;
Lesage et al. 2005; Nichols et al. 2005). In addition,
Kachergus et al. (2005) demonstrated that, in 13 families
of European descent, G2019S-mutation carriers shared
a small ancestral haplotype, suggestive of a common
founder.
In our sample of 198 affected probands from families
with PD that is compatible with autosomal dominant in-
heritance, mostly from France and North Africa, we iden-
tified a total of 13 LRRK2 G2019S-mutation carriers,
one of whom was homozygous for this mutation. Five
were of European descent (two from France and one each
from Portugal, Belgium, and The Netherlands), one was
from North America, and seven were from North Africa.
Surprisingly, one 60-year-old healthy French control in-
dividual also carried the same mutation.
To determine whether a common haplotype was also
shared by the G2019S carriers in our series, all available
family members of the 14 LRRK2-positive families were
genotyped for the 17 chromosome 12q microsatellite
markers and four SNPs, described elsewhere (Kachergus
et al. 2005), that span a 16-Mb region that includes the
LRRK2 gene. Seven markers (three microsatellites and
four SNPs) were located within the gene. A total of 62
individuals were analyzed: 40 G2019S carriers (23 af-
fected and 17 unaffected) and 22 noncarriers, 2 of whom
were affected. The microsatellites were genotyped by mul-
tiplexing appropriate labeled primers. The fluorescent
PCR products were then pooled for analysis, in two runs,
on an ABI 3730 automated sequencer. Results were an-
alyzed with GeneMapper 3.5 software (Applied Biosys-
tems). Two DNA samples from CEPH reference families
1331-01 and 1331-02 were used as external standards,
to control for consistency between runs. The four LRRK2
SNPs were genotyped by using the SnapShot multiplex
kit (Applied Biosystems), in accordance with the manu-
facturer’s instructions. Haplotypes were constructed us-
ing the Merlin program (Abecasis et al. 2002; Center
for Statistical Genetics), and their frequencies were es-
timated with the expectation-maximization algorithm
(Excoffier and Slatkin 1995). The difference in haplotype
distribution between mutation carriers and noncarriers
was evaluated by x2 and Fisher’s exact tests. Marker-
allele frequencies and marker positions were described
elsewhere (Kachergus et al. 2005). The age of the mu-
tation was evaluated by estimating the age of the most
recent common ancestor of the G2019S-mutation car-
riers on the basis of information from their shared hap-
lotypes (Genin et al. 2004).
The LRRK2 haplotype that was associated with the
G2019S mutation in all families originating from Europe
and North Africa (fig. 1) was consistent with that de-
scribed by Kachergus et al. (2005). However, the shared
region was smaller than the 145–154 kb previously pub-
lished, which reduces the common haplotype to only 60
kb. This minimal haplotype (T-254-A-G-A-154) con-
sisting of six adjacent markers spanning the region be-
tween SNP rs7966550 (Entrez SNP) in exon 22 of the
LRRK2 gene and microsatellite marker D12S2518 in
intron 45 flanking the G2019S mutation in exon 41 was
determined in French family 030, in which 29 members
in two generations were available for study. Parental
phases could also be unambiguously determined in six
other families. In the remaining families, the haplotype
could not be reconstructed unambiguously from the
shared region, but the genotypes were all compatible
with the presence of the common haplotype. In the ma-
jority of families, the shared region extended farther than
the minimal haplotype, particularly 3′ of the LRRK2
gene, and independent of geographical origin. The com-
mon haplotype was also shared by five (24.7%) non-
